Key terms
About LMAT
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LMAT news
May 03
10:25am ET
Buy Rating Affirmed: LeMaitre Vascular’s Strong Performance and Upward Financial Trajectory
May 03
10:14am ET
LeMaitre price target raised to $79 from $69 at Barrington
May 03
8:55am ET
Lake Street Sticks to Its Buy Rating for Lemaitre Vascular (LMAT)
May 03
8:07am ET
Oppenheimer Reaffirms Their Buy Rating on Lemaitre Vascular (LMAT)
May 03
6:49am ET
LeMaitre price target raised to $77 from $72 at JMP Securities
May 03
4:16am ET
KeyBanc Keeps Their Hold Rating on Lemaitre Vascular (LMAT)
May 03
12:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
May 02
4:44pm ET
LeMaitre sees FY24 EPS $1.73-$1.84, consensus $1.65
May 02
4:43pm ET
LeMaitre sees Q2 EPS 45c-50c, consensus 44c
May 02
4:42pm ET
LeMaitre reports Q1 EPS 44c, consensus 39c
Apr 25
7:25pm ET
Buy Rating Affirmed: LeMaitre Vascular’s Growth and Profitability Outlook
Apr 25
7:14pm ET
LeMaitre upgraded to Buy from Hold at Stifel
Feb 28
9:45am ET
Lemaitre Vascular’s Strong Performance and Positive Outlook Justify Buy Rating
Feb 28
9:37am ET
LeMaitre price target raised to $69 from $66 at Barrington
Feb 28
7:46am ET
Lemaitre Vascular (LMAT) Receives a Buy from Oppenheimer
Feb 28
6:36am ET
LeMaitre price target raised to $72 from $60 at JMP Securities
Feb 28
12:50am ET
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Lemaitre Vascular (LMAT) and Agilon Health (AGL)
Feb 27
4:18pm ET
LeMaitre ammpimces stock buyback program up to $50M
Feb 27
4:17pm ET
LeMaitre sees 2024 EPS $1.60-$1.71, consensus $1.53
Feb 27
4:17pm ET
LeMaitre sees Q1 EPS 36c-41c, consensus 34c
Feb 27
4:16pm ET
LeMaitre reports Q4 EPS 38c, consensus 36c
Feb 26
8:50am ET
Analysts’ Top Healthcare Picks: Lemaitre Vascular (LMAT), Silk Road Medical (SILK)
Feb 06
9:55am ET
Tesla downgraded, UPS upgraded: Wall Street’s top analyst calls
Feb 06
4:48am ET
LeMaitre resumed with a Sector Weight at KeyBanc
No recent press releases are available for LMAT
LMAT Financials
Key terms
Ad Feedback
LMAT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LMAT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
